EIF4EBP1 and neoplasm: Another advantage of SBI-756 compared to TOR-KI treatment is its ability to suppress cap-dependent translation among cells lacking 4E-BP1, a finding relevant to tumours with reduced ratio of 4E-BPs to eIF4E.